Crystal habit patents claim the external shape and morphology of a crystalline particle — needle, plate, spherical and so on — and the process conditions used to control that shape, whereas polymorph patents claim a distinct internal crystal lattice arrangement of the same molecule. The two frequently overlap in practice because changing habit often accompanies a polymorphic transition, but this landscape is scoped specifically to habit and its downstream manufacturing consequences: filtration rate, bulk density, flowability, milling requirement and tabletting behaviour. A claim that only recites a melting point or XRPD pattern without tying it to a processability outcome sits outside this scope.

Filing volume rose to a peak of 280 records in 2021 and had fallen to 116 by 2024, a -59% change over that span. This kind of pullback after a peak year is common once early movers have covered the most obvious combinations of solvent, anti-solvent and surfactant conditions, leaving fewer novel process claims for later filers. It is worth noting that 2025 and 2026 figures in any such dataset are understated because publication typically lags the actual filing date by around 18 months, so the most recent one to two years should not be read as confirming a continued decline.

The field is led by a small group of pharmaceutical and specialty-chemical companies, with the top assignee holding 508 records against 104 at fifth place and 55 at tenth — a meaningful gap that points to a sustained filing programme rather than incidental coverage. Several of the leading names are linked through co-assignee filings, most likely reflecting related corporate entities filing jointly across jurisdictions. Even so, the top ten account for only 41.8% of the 3,697 records in scope, so a large share of the field sits with companies outside the most visible names.

The technology composition data shows a heavy skew toward formulation and therapeutic-activity classes (A61K at 54.4%, C07D at 44.3%, A61P at 39.8% of records), while process-oriented classes such as B01J (chemical and physical processes) and C11D (detergents and cleaning compositions) sit under 5%. That gap suggests process-equipment claims — milling parameters tuned to specific needle habits, continuous filtration setups, or bulk-density-targeted anti-solvent addition sequences — are comparatively under-claimed relative to composition-of-matter claims on the crystal form itself.

Not necessarily. Citation counts inside a searched patent corpus accumulate over time, so older records have simply had more years to be cited and tend to dominate any most-cited list regardless of current relevance. A citation count is better read as a signal of historical influence on later filings in the same space than as an indicator that the underlying technology or claim is still central to today's commercial activity. Checking the filing date and current legal status alongside the citation count gives a more reliable read on relevance.